/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

Zevra Therapeutics Inc share price today is $10, up -2.16%. The stock opened at $10.18 against the previous close of $10.41, with an intraday high of $10.3 and low of $9.78.

style

pb-0

Zevra Therapeutics Inc

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$10 -0.0216(-2.16%) ZVRA at 13 Mar 2026 04:01 PM Biotechnology

Lowest Today 9.78

Highest Today 10.3

Today’s Open 10.18

Prev. Close 10.41

52 Week High 13.16

52 Week Low 6.19

Day’s Range: Low 9.78 High 10.3

52-Week Range: Low 6.19 High 13.16

Zevra Therapeutics Inc Institutional Holdings

Zevra Therapeutics Inc Market Status

Strong Buy: 4

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

Zevra Therapeutics Inc Fundamentals

Market Cap 586.06 M

PB Ratio 4.401

PE Ratio 22.1489

Enterprise Value 449.27 M

Total Assets 284.73 M

Volume 1386881

Zevra Therapeutics Inc Company Financials

Annual Revenue FY23:16563000 16.6M, FY22:10458000 10.5M, FY21:28650000 28.7M, FY20:13288000 13.3M, FY19:12839000 12.8M

Annual Profit FY23:15474000 15.5M, FY22:10115000 10.1M, FY21:26591000 26.6M, FY20:11983000 12.0M, FY19:9894000 9.9M

Annual Net worth FY23:-39917000 -39.9M, FY22:-41543000 -41.5M, FY21:-8555000 -8.6M, FY20:-12760000 -12.8M, FY19:-24522000 -24.5M

Quarterly Revenue Q3/2025:26063000 26.1M, Q2/2025:25881000 25.9M, Q1/2025:20401000 20.4M, Q3/2024:3695000 3.7M, Q2/2024:4449000 4.4M

Quarterly Profit Q3/2025:24510000 24.5M, Q2/2025:13502000 13.5M, Q1/2025:19056000 19.1M, Q3/2024:1392000 1.4M, Q2/2024:876000 0.9M

Quarterly Net worth Q3/2025:-544000 -0.5M, Q2/2025:74707000 74.7M, Q1/2025:-3099000 -3.1M, Q3/2024:-33225000 -33.2M, Q2/2024:-19925000 -19.9M

About Zevra Therapeutics Inc & investment objective

Company Information Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Organisation Biotechnology

Employees 61

Industry Biotechnology

CEO Mr. Neil F. McFarlane

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*